Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: essensys loss widens; Carclo demand strong

Tue, 18th Oct 2022 22:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

essensys PLC - London-based software and cloud services for flexible workspace industry - In year ended July 31, pretax loss widens to GBP11.1 million from GBP2.9 million a year prior. Revenue rises to GBP23.3 million from GBP22.0 million. Administrative expenses grows to GBP24.3 million from GBP16.5 million. Chief Executive Mark Furness says period was a year of "progress and resilience". "Momentum with strategic customers remains and underpins a significant pipeline of opportunities. The quality of our customer base has helped us to manage near-term headwinds such as delays to sales cycles and capital deployment, some portfolio rebalancing among our larger flexible workspace operators and the expected churn at the tail-end of our customer base," he adds.

----------

Carclo PLC - West Yorkshire-based plastic parts manufacturer - Says demand in first six months of its financial year, ending March 31 2023, has been "strong", resulting in sales marginally ahead of board expectations and ahead of the prior year. It adds: "The inflation and supply chain challenges experienced in the first half are expected to continue through the remainder of the financial year. Our initiatives to further enhance operational efficiency and to offset inflationary price increases are key focus areas for the second half. Increases in borrowing costs are expected in the second half driven by increases in both the level of debt and interest rates."

----------

Angle PLC - Surrey, England-based medical diagnostics company - Decides to close facilities in Toronto, Canada in an orderly wind down. Notes it retains its high-specification clinical laboratory facility in Plymouth Meeting, Pennsylvania, US, as its central hub for North American activities. Says decision is part of commitment to tightly control costs and focus on near-term commercialisation of Parsortix system for cancer liquid biopsy. Hopes to reduce costs by GBP2.6 million in 2023, rising to GBP4.0 million after.

----------

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - Pretax loss in year to June narrows to GBP2.6 million versus GBP2.9 million loss in 15 months to June 30, 2021. Revenue multiplies to GBP4.0 million from GBP1.6 million. Administrative expenses rise to GBP4.4 million from GBP3.1 million. Chief Executive Arron Tolley says: "Aptamer has maintained a solid pace of progress over the past year, having seen success in both expanding current partnerships and winning new contracts. Commercial traction continues to increase in Europe, US and APAC regions." Sees strong revenue growth in current financial year.

----------

Open Orphan PLC - London-based research organisation testing infectious and respiratory disease products - Appoints Stephen Pinkerton as chief financial officer, to replace Leo Toole who will step down at end of 2022. Pinkerton is chartered accountant with over 25 years of experience in senior financial roles and has served as Commercial Financial Director of hVIVO since July 2017. Also notes Cathal Friel is reverting to Non-Executive Chair after Yamin Khan appointment of chief executive officer.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2022 11:45

Open Orphan's hVIVO wins GBP14.7 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said it's subsidiary hVIVO signed a GBP14.7 million contract for an influenza characterisation study and a follow on influenza human challenge study.

Read more
31 May 2022 16:05

UK earnings, trading statements calendar - next 7 days

Wednesday 1 June  
Impax Asset Management Group PLCHalf Year Results
Dr Martens PLCFull Year Results
Thursday 2 June  
no events scheduled 
Friday  3 June  
no events scheduled  
Monday 6 June  
Atrato Onsite Energy PLCHalf Year Results
Empiric Student Property PLCTrading Statement
Jadestone Energy PLCFull Year Results
Tuesday 7 June  
Gooch & Housego PLCHalf Year Results
LXi REIT PLCFull Year Results
NewRiver REIT PLCFull Year Results
Open Orphan PLCFull Year Results
Schroder Real Estate Investment Trust LtdFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
18 May 2022 16:43

Open Orphan's hVIVO wins GBP7.3 million influenza study contract

(Alliance News) - Open Orphan PLC on Wednesday said its subsidiary hVIVO Ltd has signed a GBP7.3 million contract.

Read more
18 May 2022 15:15

Open Orphan wins £7.3m human flu study contract

(Sharecast News) - Specialist contract research organisation Open Orphan announced on Wednesday that its hVIVO subsidiary has signed a £7.3m flu human challenge study contract with an unnamed biotechnology company, to test its antiviral product using hVIVO's influenza human challenge study model.

Read more
6 May 2022 19:11

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 May 2022 14:53

IN BRIEF: Open Oprhan wins contract for vaccine field site study

Open Orphan PLC - London-based pharmaceutical services - Subsidiary hVIVO is awarded new study with existing unnamed pharmacetical client to act as vaccination site for the client's respiratory syncytial virus vaccine candidate. hVIVO's specialist arm FluCamp will recruit 60 healthy volunteers to the new site clinic at Plumbers Row where trials will take place.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Apr 2022 20:23

IN BRIEF: Open Orphan Covid study results published in Nature Medicine

Open Orphan PLC - London-based pharmaceutical services - Says Thursday that results from the world's first Covid-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. Says study showed the SARS-CoV-2 human challenge was safe in healthy young adults and provided insights into the course of Covid-19 infection with potential positive public health implications. With the characterisation study disease modelling data completed, and human challenge model established, Open Orphan says it should be able to conduct Covid-19 human challenge studies in 2022.

Read more
25 Mar 2022 14:10

IN BRIEF: Open Orphan wins GBP5 million human challenge study pact

Open Orphan PLC - London-based pharmaceutical services firm - Says its subsidiary, hVIVO, wins contract with a European biotechnology company for a human challenge study. The GBP5 million contract with a European biotech seeks to test hVIVO's intravenous antiviral candidate. The study on the respiratory syncytial virus is expected to commence this year. Revenue from the deal will be recognised across 2022 and 2023.

Read more
25 Mar 2022 09:39

Open Orphan wins £5m contract for human study in RSV

(Sharecast News) - Open Orphan announced on Friday that its hVIVO subsidiary has signed a £5m respiratory syncytial virus (RSV) human challenge study contract with an unnamed European biotechnology company, to test its intravenous antiviral candidate.

Read more
8 Mar 2022 19:37

IN BRIEF: Open Orphan expects to report profitable 2021 performance

Open Orphan PLC - London-based pharmaceutical services - For 2021, expects to report earnings before interest, tax, depreciation and amortisation, on revenue which is set to be GBP40 million, up from GBP20.6 million in 2020. For 2022, the company is targeting GBP50 million in non-Covid work revenue.

Read more
24 Feb 2022 15:24

Open Orphan appoints Mo Khan as its new chief executive

(Sharecast News) - Contract research organisation Open Orphan announced the appointment of Yamin 'Mo' Khan as its chief executive officer on Thursday, with immediate effect.

Read more
24 Feb 2022 14:48

IN BRIEF: Open Orphan non-exec Mo Khan switches to chief executive

Open Orphan PLC - London-based pharmaceutical services - Moves Non-Executive Director Mo Khan to chief executive officer, effective immediately. Khan had joined the Open Orphan board back in October. The company notes he has 25 years of clinical research experience. Cathal Friel remains executive chair, while Open Orphan will aim to find a new independent non-executive director within the next six months.

Read more
22 Feb 2022 21:57

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
17 Feb 2022 20:13

IN BRIEF: Positive results from Open Orphan human challenge study

Open Orphan PLC - pharmaceutical services provider - Sees positive results from a human challenge study assessing its respiratory syncytial virus antiviral candidate, EDP-938. Says results from the study have been published in The New England Journal of Medicine. hVIVO, a subsidiary of Open Orphan, conducted the Phase 2a, double-blind, placebo-controlled trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.